



dievini comments on press releases about CureVac

Walldorf, Germany, 15 March 2020 – dievini Hopp BioTech holding GmbH & Co. KG, a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies, comments on the press reports regarding a potential exclusive distribution of a vaccine currently under development by CureVac against the coronavirus. dievini has been a shareholder of CureVac AG, Tuebingen, since 2005 and holds over 80 % of the shares. The second largest shareholder is the Bill & Melinda Gates Foundation, which develops vaccines against several infectious diseases together with CureVac.

“Since we founded the company in 2005, I have been convinced that the understanding of molecular processes will transform the diagnosis and therapy of even the most severe diseases to help patients worldwide,” says Dietmar Hopp. “I am equally committed to the goal of protecting all people from infections and improving therapies for patients worldwide, ideally curing them, as well as to my intention of creating sustainable innovative infrastructure and jobs in Germany. Hopefully, we will soon succeed in developing an effective vaccine against the coronavirus. This vaccine should be available not only regionally, but to people all over the world in solidarity to help and protect them. I would be glad if this could be achieved from Germany through my long-term investment.”

dievini holds investments in ten companies – seven in Germany, two in Switzerland, one in Italy – almost all of which are developing diagnostics, therapeutics, and vaccines against serious diseases such as cancer, bacterial and viral infections, and neurodegenerative disorders.

For further information, please contact:

dievini Hopp BioTech holding GmbH & Co. KG

Aggi Kibgis

contact@dievini.com

Media contact

MC Services AG

Katja Arnold

T: +49 (0)89 210228840

katja.arnold@mc-services.eu